Department of Internal Medicine

Oncology

Research

JOURNAL PUBLICATIONS (2010 - 2014):
  1. Gibbon VE, Strkalj G, Paximadis M, Ruff P and Penny CB. The sex profile of skeletal remains from a cemetery of Chinese indentured labourers in South Africa. South African Journal of Science 2010; 106 (7/8) (Art #191): 65-68.
  2. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel E, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasiñska-Morawiec M, Šmakal M, Canon J-L, Rother M, Oliner K, Wolf M and Gansert J. Randomized, phase 3 study (PRIME) of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2010; 28(31): 4697-4705.
  3. Saglio G, Kim DW, Issaragtisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. N Engl J Med 2010; Jun 17; 362(24): 2251-2259.
  4. Vorobiof DA and Ruff P. Cancer in South Africa and the Role of the National Cancer Registry. The ASCO Post 2011; 2(7).
  5. Louw V, Dreosti LM, Ruff P, Jogessar V, Moodley D, Novitzky N and Willem P. Guideline: Recommendations for the management of adult chronic myeloid leukaemia in South Africa. South African Medical Journal 2011; 101(11): 840-846.
  6. Louw V, Bassa F, Chan SW, Dreosti L, du Toit M, Ferreira M, Gartrell F, Gunther K, Jogessar V, Littleton N, Mahlangu J, McDonald A, Patel M, Pool R, Ruff P, Schmidt A, Sissolak G, Swart A, Verburgh E and Webb M. Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa. South African Medical Journal 2011; 101(12): 900-906.
  7. Abratt RP, Dreosti L and Ruff P. Cancer care in South Africa. Lancet Oncology 2012; 13(8): 324.
  8. Van Cutsem E, Tabernero J, Lakomi R, Prausona J, Ruff P, Van Hazel G, Moiseyenko V, Ferry D, MacKendricks J and Allegra C. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatmentof metastatic colorectal cancer (mCRC): Results of a multinational phase III trial (EFC10262-VELOUR). Journal of Clinical Oncology 2012; 30: 34999-3506.
  9. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. New England Journal of Medicine. 2013 Sep 12;369(11):1023-34.
  10. Tabernero J, Van Cutsem E, Lakomý R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial. European Journal of Cancer 2014 Jan 5.
  11. Logan TF, Szczylik C, Tannir N, Benedetto P, Makhson A, McDermott D, Ruff P, Mikulás J, Dutcher JP, Bverkenblit A, Galand L, Krygowski M and Hudes G. Effect of Nephrectomy Status on Temsirolimus Efficacy in Patients with Advanced Poor-Prognostic Renal Cell Cancer. Medical Oncology 2014; (submitted).
  12. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel E, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasińska-Morawiec M, Šmakal M, Canon J-L, Rother M, Oliner K, Wolf M and Gansert J. Final results from PRIME: Randomized phase 3 study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). European Journal of Cancer 2014 (submitted).
  13. Price TJ, Peeters M, Tae Won Kim, Jin Li, Cascinu F, Ruff P, Atilli Satya Suresh, Thomas A, Tjulandin S, Zhang K, Murugappan S and Sidhu R. ASPECCT: A randomized, multicenter, open-label, phase 3 study of panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. Lancet Oncology 2014 (in press).

CLINICAL RESEARCH STUDIES:

Runs JHB Oncology Syndicate through Wits Health Consortium with active research in many local and international collaborative clinical trials in Oncology:

Clinical Trials Co-ordinated by Dr. S. Hansa and Dr. A. Hemus.
  1. Phase II and III Clinical Trials of novel agents in hepatocellular carcinoma with sorafenib, sunitinib, erlotinib, everolimus, clofazimine, eniluracil, pegylated liposomal doxorubicin and nolatrexed: (Since 1993).
  2. Phase I, II and III Clinical Trials with edrocolomab, irinotecan, raltitrexed, eniluracil, capecitabine, oxaliplatin, bevacizumab, aflibercept, sunitinib, panitumumab and cetuximab in Stage 3 and 4 colorectal cancer: (Since 1996).
  3. Phase III Clinical Trials with axitinib, gefitinib, erlotinib, vandetanib, vinorelbine, pemetrexed, cetuximab, crizotinib, vorinostat and topotecan in lung cancer: (Since 2000).
  4. Phase I, II and III Clinical Trials with interferon-α, Pegasys®, imatinib, nilotinib and dasatinib in chronic myelogenous leukaemia: (Since 1996).
  5. Phase III Clinical Trials with axitinib, tipifarnib and exatecan in pancreatic cancer: (2000-2008).
  6. Phase III Clinical Trials with antiemetic agents including 5HT-3 and NK-1 inhibitors: (Since 1992).
  7. Phase III Clinical Trials with traztuzumab, docetaxel, zosiquadar, vinflunine, letrozole, lapatinib, tesmelifine, erebulin, neratinib and dexrozoxane in breast cancer: (Since 2002).
  8. Phase III Clinical Trials with temsirolimus and everolimus in renal cell cancer: (2003-2010).
  9. Phase III Clinical Trials with thalidomide, vorinostat and panobinostat in multiple myeloma: (Since 2005).

JOURNAL REVIEWER:
PROF RUFF
  1. Current Oncology (Canada) (2010).
  2. European Journal of Cancer (2011).
  3. Journal of Apheresis (2010).
  4. New England Journal of Medicine (2013).

DR PENNY
  1. American Journal of Clinical Pathology (2012)